Adicet presents preclinical data for adi-002, a gpc3-targeted development candidate for solid tumors, at the sitc annual meeting

Adicet's allogeneic gamma delta car-t cell therapy candidate is designed to combine car targeting and cell intrinsic il-15 armoring with the innate and adaptive immune effector functions of the company's gamma delta t cell platform
ACET Ratings Summary
ACET Quant Ranking